Literature DB >> 21551242

MicroRNA signatures: novel biomarker for colorectal cancer?

Xiaoya Luo1, Barbara Burwinkel, Sha Tao, Hermann Brenner.   

Abstract

Aberrant microRNA (miRNA) expression might be of potential use as diagnostic and prognostic biomarker for cancers. We reviewed studies published until March 2011 which assessed expression of miRNAs in colorectal cancer (CRC)/adenoma tissue and normal colorectal mucosa and in plasma of CRC/adenoma patients and healthy controls. Overall, 20 studies that investigated miRNA expression in tissue and 3 studies that investigated miRNA levels in plasma were included. A total of 160 miRNAs were found to be dysregulated in CRC. MiR-20a and miR-31 were found to be significantly upregulated in more than one study, and miR-143 and miR-145 were found to be significantly downregulated in CRC tissue in six or more studies. MiR-92a was significantly upregulated in CRC patients in two of the plasma-based studies and in CRC tissue in one of the tissue-based studies. Our results provide timely and relevant information for miRNAs as potential diagnostic biomarkers for CRC. The expression of miRNAs in plasma may be indicative of presence of CRC. Larger diagnostic studies are needed to evaluate potential use of miRNA expression in early detection and diagnosis of CRC. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21551242     DOI: 10.1158/1055-9965.EPI-11-0035

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  96 in total

1.  Micromanaging the classification of colon cancer: the role of the microRNAome.

Authors:  Eduardo Vilar; Josep Tabernero; Stephen B Gruber
Journal:  Clin Cancer Res       Date:  2011-10-21       Impact factor: 12.531

Review 2.  The role of microRNAs in colorectal cancer.

Authors:  Aaron J Schetter; Hirokazu Okayama; Curtis C Harris
Journal:  Cancer J       Date:  2012 May-Jun       Impact factor: 3.360

3.  miR-15a-5p, A Novel Prognostic Biomarker, Predicting Recurrent Colorectal Adenocarcinoma.

Authors:  Christos K Kontos; Panagiotis Tsiakanikas; Margaritis Avgeris; Iordanis N Papadopoulos; Andreas Scorilas
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

Review 4.  Roles of microRNAs as non-invasive biomarker and therapeutic target in colorectal cancer.

Authors:  Timothy Ming-Hun Wan; Deepak Narayanan Iyer; Lui Ng
Journal:  Histol Histopathol       Date:  2019-10-16       Impact factor: 2.303

Review 5.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

6.  Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.

Authors:  Prasant Yadav; Masroor Mirza; Kajal Nandi; S K Jain; R C M Kaza; Nita Khurana; P C Ray; Alpana Saxena
Journal:  Tumour Biol       Date:  2016-09-30

7.  MicroRNA-155 expression inversely correlates with pathologic stage of gastric cancer and it inhibits gastric cancer cell growth by targeting cyclin D1.

Authors:  Zhijun Ma; Yulan Ma; Qinghua Xia; Yong Li; Ruidong Li; Weilong Chang; Jinhuang Chen; Zhengwei Leng; Kaixiong Tao
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-08       Impact factor: 4.553

Review 8.  Study of apoptosis-related interactions in colorectal cancer.

Authors:  Himanshu Arora; Rehana Qureshi; M A Rizvi; Sharad Shrivastava; Mordhwaj S Parihar
Journal:  Tumour Biol       Date:  2016-09-15

9.  Locked nucleic acid inhibits miR-92a-3p in human colorectal cancer, induces apoptosis and inhibits cell proliferation.

Authors:  S Ahmadi; M Sharifi; R Salehi
Journal:  Cancer Gene Ther       Date:  2016-05-20       Impact factor: 5.987

10.  The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer.

Authors:  Liselle C Bovell; Chandrakumar Shanmugam; Balananda-Dhurjati K Putcha; Venkat R Katkoori; Bin Zhang; Sejong Bae; Karan P Singh; William E Grizzle; Upender Manne
Journal:  Clin Cancer Res       Date:  2013-05-29       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.